Implementation of the Infection Risk Scan (IRIS) in nine hospitals in the Belgian-Dutch border region (i-4-1-Health project).
Benchmarking
Guidelines
Infection prevention
Surveillance
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
28 02 2022
28 02 2022
Historique:
received:
30
12
2021
accepted:
07
02
2022
entrez:
1
3
2022
pubmed:
2
3
2022
medline:
17
3
2022
Statut:
epublish
Résumé
A tool, the Infection Risk Scan has been developed to measure the quality of infection control and antimicrobial use. This tool measures various patient-, ward- and care-related variables in a standardized way. We describe the implementation of this tool in nine hospitals in the Dutch/Belgian border area and the obtained results. The IRIS consists of a set of objective and reproducible measurements: patient comorbidities, (appropriate) use of indwelling medical devices, (appropriate) use of antimicrobial therapy, rectal carriage of Extended-spectrum beta-lactamase producing Enterobacterales and their clonal relatedness, environmental contamination, hand hygiene performance, personal hygiene of health care workers and presence of infection prevention preconditions. The Infection Risk Scan was implemented by an expert team. In each setting, local infection control practitioners were trained to achieve a standardized implementation of the tool and an unambiguous assessment of data. The IRIS was implemented in 34 wards in six Dutch and three Belgian hospitals. The tool provided ward specific results and revealed differences between wards and countries. There were significant differences in the prevalence of ESBL-E carriage between countries (Belgium: 15% versus The Netherlands: 9.6%), environmental contamination (median adenosine triphosphate (ATP) level Belgium: 431 versus median ATP level The Netherlands: 793) and calculated hand hygiene actions based on alcohol based handrub consumption (Belgium: 12.5/day versus The Netherlands: 6.3/day) were found. The Infection risk Scan was successfully implemented in multiple hospitals in a large cross-border project and provided data that made the quality of infection control and antimicrobial use more transparent. The observed differences provide potential targets for improvement of the quality of care.
Sections du résumé
BACKGROUND
A tool, the Infection Risk Scan has been developed to measure the quality of infection control and antimicrobial use. This tool measures various patient-, ward- and care-related variables in a standardized way. We describe the implementation of this tool in nine hospitals in the Dutch/Belgian border area and the obtained results.
METHODS
The IRIS consists of a set of objective and reproducible measurements: patient comorbidities, (appropriate) use of indwelling medical devices, (appropriate) use of antimicrobial therapy, rectal carriage of Extended-spectrum beta-lactamase producing Enterobacterales and their clonal relatedness, environmental contamination, hand hygiene performance, personal hygiene of health care workers and presence of infection prevention preconditions. The Infection Risk Scan was implemented by an expert team. In each setting, local infection control practitioners were trained to achieve a standardized implementation of the tool and an unambiguous assessment of data.
RESULTS
The IRIS was implemented in 34 wards in six Dutch and three Belgian hospitals. The tool provided ward specific results and revealed differences between wards and countries. There were significant differences in the prevalence of ESBL-E carriage between countries (Belgium: 15% versus The Netherlands: 9.6%), environmental contamination (median adenosine triphosphate (ATP) level Belgium: 431 versus median ATP level The Netherlands: 793) and calculated hand hygiene actions based on alcohol based handrub consumption (Belgium: 12.5/day versus The Netherlands: 6.3/day) were found.
CONCLUSION
The Infection risk Scan was successfully implemented in multiple hospitals in a large cross-border project and provided data that made the quality of infection control and antimicrobial use more transparent. The observed differences provide potential targets for improvement of the quality of care.
Identifiants
pubmed: 35227333
doi: 10.1186/s13756-022-01083-1
pii: 10.1186/s13756-022-01083-1
pmc: PMC8887653
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
43Investigateurs
Lieke van Alphen
(L)
Nicole van den Braak
(N)
Caroline Broucke
(C)
Anton Buiting
(A)
Liselotte Coorevits
(L)
Sara Dequeker
(S)
Jeroen Dewulf
(J)
Wouter Dhaeze
(W)
Bram Diederen
(B)
Helen Ewalts
(H)
Herman Goossens
(H)
Inge Gyssens
(I)
Casper den Heijer
(C)
Christian Hoebe
(C)
Casper Jamin
(C)
Patricia Jansingh
(P)
Jan Kluytmans
(J)
Marjolein Kluytmans-van den Bergh
(M)
Stefanie van Kleef-van Koeveringe
(S)
Sien De Koster
(S)
Christine Lammens
(C)
Isabel Leroux-Roels
(I)
Hanna Masson
(H)
Ellen Nieuwkoop
(E)
Anita Van Oosten
(A)
Natascha Perales Selva
(NP)
Merel Postma
(M)
Stijn Raven
(S)
Veroniek Saegeman
(V)
Paul Savelkoul
(P)
Annette Schuermans
(A)
Nathalie Sleeckx
(N)
Krista van der Slikke
(K)
Arjan Stegeman
(A)
Tijs Tobias
(T)
Paulien Tolsma
(P)
Jacobien Veenemans
(J)
Dewi van der Vegt
(D)
Martine Verelst
(M)
Carlo Verhulst
(C)
Pascal De Waegemaeker
(P)
Veronica Weterings
(V)
Clementine Wijkmans
(C)
Patricia Willemse-Smits
(P)
Ina Willemsen
(I)
Informations de copyright
© 2022. The Author(s).
Références
Microb Genom. 2021 Aug;7(8):
pubmed: 34356004
Am J Infect Control. 2020 Apr;48(4):391-397
pubmed: 31703820
J Hosp Infect. 2003 Aug;54(4):258-66; quiz 321
pubmed: 12919755
BMC Genomics. 2018 Dec 4;19(1):870
pubmed: 30514209
Antimicrob Agents Chemother. 2007 Mar;51(3):864-7
pubmed: 17210766
J Clin Microbiol. 2018 Feb 22;56(3):
pubmed: 29263202
J Hosp Infect. 2009 Jun;72(2):140-6
pubmed: 19321226
Antimicrob Agents Chemother. 2010 Oct;54(10):4085-91
pubmed: 20660675
J Antimicrob Chemother. 2016 Apr;71(4):1076-82
pubmed: 26755493
Antimicrob Resist Infect Control. 2018 Mar 9;7:38
pubmed: 29541449
J Infect Prev. 2016 May;17(3):127-129
pubmed: 28989468
Am J Infect Control. 2011 Feb;39(1):19-26
pubmed: 21281883
Infect Control Hosp Epidemiol. 2016 Jun;37(6):707-10
pubmed: 27021950
Infect Control Hosp Epidemiol. 2009 Jul;30(7):678-84
pubmed: 19489715
Clin Microbiol Rev. 2013 Oct;26(4):744-58
pubmed: 24092853
J Hosp Infect. 2016 Apr;92(4):328-31
pubmed: 26984282
Antimicrob Resist Infect Control. 2020 May 28;9(1):77
pubmed: 32466792
Antimicrob Resist Infect Control. 2020 Jan 13;9(1):13
pubmed: 31956402
Lancet Glob Health. 2018 Jun;6(6):e619-e629
pubmed: 29681513
Ned Tijdschr Geneeskd. 2016;160:D518
pubmed: 27900923